Sudarshan Pharma [SUDARSHAN] vs Ghcl [GHCL] Detailed Stock Comparison

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Sudarshan Pharma Industries Ltd. wins in 2 metrics, Ghcl Ltd. wins in 16 metrics, with 0 ties. Ghcl Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Sudarshan Pharma Industries Ltd. Ghcl Ltd. Better
P/E Ratio (TTM) 35.73 9.54 Ghcl Ltd.
Price-to-Book Ratio 5.61 1.33 Ghcl Ltd.
Debt-to-Equity Ratio 155.50 2.66 Ghcl Ltd.
PEG Ratio N/A -0.31 N/A
EV/EBITDA 20.44 5.10 Ghcl Ltd.
Profit Margin (TTM) 3.26% 16.60% Ghcl Ltd.
Operating Margin (TTM) 5.93% 17.17% Ghcl Ltd.
EBITDA Margin (TTM) 5.93% 17.17% Ghcl Ltd.
Return on Equity 12.13% 17.89% Ghcl Ltd.
Return on Assets (TTM) 3.96% 14.91% Ghcl Ltd.
Free Cash Flow (TTM) $304.76M $3.23B Ghcl Ltd.
Dividend Yield N/A 1.97% N/A
1-Year Return 19.22% -25.88% Sudarshan Pharma Industries Ltd.
Price-to-Sales Ratio (TTM) 1.12 1.53 Sudarshan Pharma Industries Ltd.
Enterprise Value $9.53B $37.40B Ghcl Ltd.
EV/Revenue Ratio 1.48 1.22 Ghcl Ltd.
Gross Profit Margin (TTM) 12.03% 42.51% Ghcl Ltd.
Revenue per Share (TTM) $26 $321 Ghcl Ltd.
Earnings per Share (Diluted) $0.84 $53.16 Ghcl Ltd.
Beta (Stock Volatility) 0.69 -0.42 Ghcl Ltd.

Sudarshan Pharma Industries Ltd. vs Ghcl Ltd. Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Sudarshan Pharma Industries Ltd.0.29%-6.63%10.91%32.55%30.44%27.16%
Ghcl Ltd.-0.92%-3.53%-15.40%-2.81%-27.72%-20.48%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Sudarshan Pharma Industries Ltd.19.22%423.13%459.90%459.90%459.90%459.90%
Ghcl Ltd.-25.88%-6.75%66.32%167.15%1,049.75%177.09%

Performance & Financial Health Analysis: Sudarshan Pharma Industries Ltd. vs Ghcl Ltd.

MetricSUDARSHANGHCL
Market Information
Market Cap i₹7.29B₹46.18B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i307,600120,135
90 Day Avg. Volume i248,667157,777
Last Close₹34.47₹442.65
52 Week Range₹18.50 - ₹36.95₹419.00 - ₹667.20
% from 52W High-6.71%-33.66%
All-Time High₹452.70 (Sep 30, 2024)₹779.00 (Jan 27, 2025)
% from All-Time High-92.39%-43.18%
Growth Metrics
Quarterly Revenue Growth0.45%-0.03%
Quarterly Earnings Growth0.51%-0.37%
Financial Health
Profit Margin (TTM) i0.03%0.17%
Operating Margin (TTM) i0.06%0.17%
Return on Equity (TTM) i0.12%0.18%
Debt to Equity (MRQ) i155.502.66
Cash & Liquidity
Book Value per Share (MRQ)₹5.35₹380.30
Cash per Share (MRQ)₹0.11₹119.25
Operating Cash Flow (TTM) i₹8.46M₹8.25B
Levered Free Cash Flow (TTM) i₹159.55M₹6.24B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A₹12.00

Valuation & Enterprise Metrics Analysis: Sudarshan Pharma Industries Ltd. vs Ghcl Ltd.

MetricSUDARSHAN (Apr 24, 2026)GHCL (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i35.739.54
Forward P/E iN/A7.70
PEG Ratio iN/A-0.31
Price to Sales (TTM) i1.121.53
Price to Book (MRQ) i5.611.33
Market Capitalization
Market Capitalization i₹7.29B₹46.18B
Enterprise Value i₹9.53B₹37.40B
Enterprise Value Metrics
Enterprise to Revenue i1.481.22
Enterprise to EBITDA i20.445.10
Risk & Other Metrics
Beta i0.69-0.42
Book Value per Share (MRQ) i₹5.35₹380.30

Financial Statements Comparison: Sudarshan Pharma Industries Ltd. vs Ghcl Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSUDARSHAN (2025)GHCL (2025)
Revenue/Sales i5.05B31.76B
Cost of Goods Sold i4.40B17.58B
COGS % of Revenue i87.1%55.3%
Gross Profit i651.01M14.18B
Gross Margin i12.9%44.7%
Research & Development iN/AN/A
Operating Income (EBIT) i379.01M7.68B
Operating Margin i7.5%24.2%
EBITDA i407.72M9.20B
EBITDA Margin i8.1%29.0%
Pre-Tax Income i216.29M8.36B
Pre-Tax Income % of Revenue i4.3%26.3%
Income Tax i56.77M2.12B
Income Tax % of Revenue i1.1%6.7%
Net Income (Profit) i159.53M6.24B
Profit Margin i3.2%19.6%

Balance Sheet & Liquidity Metrics

MetricSUDARSHAN (2025)GHCL (2025)
Cash & Equivalents i5.51M986.30M
Total Current Assets i3.35B19.54B
Total Current Assets % of Revenue i66.3%61.5%
Total Current Liabilities i2.60B3.68B
Total Current Liabilities % of Revenue i51.4%11.6%
Long-Term Debt i104.60M805.80M
Long-Term Debt % of Revenue i2.1%2.5%
Total Shareholders Equity i1.31B34.89B
Retained Earnings iN/A33.16B
Retained Earnings % of Revenue i0.0%104.4%
Property, Plant & Equipment i200.50M989.00M

Cash Flow Statement Comparison

MetricSUDARSHAN (2025)GHCL (2025)
Operating Cash Flow i8.46M8.25B
Operating Cash Flow % of Revenue i0.2%26.0%
Capital Expenditures i-47.46M-3.02B
Free Cash Flow i304.76M3.23B
FCF Margin i6.0%10.2%
Debt Repayment iN/A-994.30M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSUDARSHANGHCL
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i240.66M91.93M
Float Shares i87.72M63.12M
% Held by Insiders i76.52%39.72%
% Held by Institutions i0.00%21.54%
% Held by Public i23.48%38.74%

Dividend Analysis & Yield Comparison: Sudarshan Pharma Industries Ltd. vs Ghcl Ltd.

MetricSUDARSHANGHCL
Last 12-Month Dividend iN/A₹12.00
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A₹13.83
3-Year Avg Dividend Yield iN/A2.50%
3-Year Total Dividends iN/A₹41.50
Ex-Dividend DateN/AJul 17, 2025